Ovatodiolide
| Code | Size | Price |
|---|
| TAR-T24573-5mg | 5mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ovatodiolide is a broad anticancer agent that acts by upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene, and dysregulating the PI3K/AKT/mTOR pathway.
CAS:
3484-37-5
Formula:
C20H24O4
Molecular Weight:
328.408
Purity:
0.98
SMILES:
CC1=C/CCC2=C[C@@H](CC(C)=C[C@@H]3OC(=O)C(=C)[C@H]3CC1)OC2=O
References
1. Tu YX, Wang SB, Fu LQ, Li SS, Guo QP, Wu Y, Mou XZ, Tong XM. Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. Oncotarget. 2017 Dec 14;9(3):3267-3277. doi: 10.18632/oncotarget.23231. eCollection 2018 Jan 9. PubMed PMID: 29423045; PubMed Central PMCID: PMC5790462.
2. Yu CY, Jerry Teng CL, Hung PS, Cheng CC, Hsu SL, Hwang GY, Tzeng YM. Ovatodiolide isolated from Anisomeles indica induces cell cycle G2/M arrest and apoptosis via a ROS-dependent ATM/ATR signaling pathways. Eur J Pharmacol. 2018 Jan 15;819:16-29. doi: 10.1016/j.ejphar.2017.09.050. Epub 2017 Oct 3. PubMed PMID: 28986085.
3. Wang CN, Lee YL, Lin YP, Chung WH, Tzeng YM, Lee CC. Ovatodiolide suppresses allergic airway inflammation and hyperresponsiveness in a murine model of asthma. Eur J Pharmacol. 2017 Oct 5;812:9-17. doi: 10.1016/j.ejphar.2017.06.036. Epub 2017 Jun 27. PubMed PMID: 28666799.
4. Huang YJ, Yang CK, Wei PL, Huynh TT, Whang-Peng J, Meng TC, Hsiao M, Tzeng YM, Wu AT, Yen Y. Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways. J Hematol Oncol. 2017 Feb 28;10(1):60. doi: 10.1186/s13045-017-0421-3. PubMed PMID: 28241877; PubMed Central PMCID: PMC5329923.